Conclusions: FGFR1 overexpression could be different in primary RCC and metastasis of same patient. Expression of FGFR1 was found in 100% of renal tumors that responded to anti-FGFR therapy and in 18% ...

Morice, A., et al. (2025). FGFR antagonists restore defective mandibular bone repair in a mouse model of osteochondrodysplasia. Bone Research. doi.org/10.1038/s41413-024-00385-x.

Background: A substantial proportion of patients with squamous lung cell carcinoma (SQCLC) (46%) exhibit tumor overexpression of fibroblast growth factor receptor (FGFR) messenger ribonucleic acid ...

The study calls for further clinical trials to test FGFR and NOTCH inhibitors in ETMR patients and explores antisense therapies targeting C19MC miRNAs, which have shown promise in lab settings.

A new study explores the potential of fibroblast growth factor receptor (FGFR) antagonists in restoring defective mandibular bone repair in mouse models of osteochondrodysplasia, a group of ...

" FGFR -altered tumors typically are immunologically cold and have limited responses to immunotherapy. The goal of this trial was to determine if combining immunotherapy and FGFR-targeted therapy ...

Among the 12 patients with FGF/FGFR gene aberrations who have completed at least one tumor assessment, the overall response rate (ORR) was 33.3%, including 1 patient (8.3%) of cholangiocarcinoma ...

In their review, the authors describe the FGFR pathway, its role in oncogenesis, current FGFR inhibitors, the role these inhibitors play in treatment cholangiocarcinoma, and the future of the field.

Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders, such as craniosynostosis and chondrodysplasia, which severely affect ...